---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-004552"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T03:58:36.856600+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo reports Q4 net loss $52M, cash down to $307.5M; halts sickle cell investment, seeks partner

## Summary
- Q4 2022 net loss $52.0M ($0.32/share) vs $37.5M loss in Q4 2021.
- Full year 2022 net loss $192.3M ($1.25/share) vs $178.3M in 2021.
- Cash and marketable securities $307.5M at Dec 31, 2022, down from $464.7M a year ago.
- 2023 GAAP operating expense guidance $310-330M; non-GAAP $275-295M.
- Discontinuing material investments in sickle cell program; seeking collaboration partner for Phase 3.

## SEC filing metadata
- accession: 0001628280-23-004552
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828023004552/0001628280-23-004552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828023004552/sgmo-20230222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-004552
- JSON: https://secwatch.observer/filing/0001628280-23-004552.json
- Plain text: https://secwatch.observer/filing/0001628280-23-004552.txt

## Key facts
- Earnings Releases
  SANGAMO THERAPEUTICS, INC reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 22, 2023, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022 (the “Press Release”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000162828023004552/0001628280-23-004552-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.